Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2021 - 2026)

Amylyx Pharmaceuticals' Change in Accured Expenses history runs 6 years deep, the most recent figure standing at -$6.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 43.83% year-over-year to -$6.7 million in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 97.83% increase from a year earlier, with the FY2025 full-year figure at -$6.6 million, up 88.97% from the prior year.
• Change in Accured Expenses retreated to -$6.7 million in Q1 2026 per AMLX's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $20.8 million in Q4 2023 and bottomed at -$26.4 million in Q4 2024.
• The 5-year median for Change in Accured Expenses is -$146000.0 (2023), against an average of -$1.5 million.
• Across the five-year window, Change in Accured Expenses jumped 4109.43% in 2022 and plunged 8879.45% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $15.6 million in 2022, then surged by 33.01% to $20.8 million in 2023, then sank by 227.07% to -$26.4 million in 2024, then jumped by 95.42% to -$1.2 million in 2025, then sank by 452.03% to -$6.7 million in 2026.
• Per Business Quant, the three latest AMLX Change in Accured Expenses figures stand at -$6.7 million (Q1 2026), -$1.2 million (Q4 2025), and $1.1 million (Q3 2025).